Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q2 2026 Earnings Presentation
18 slides from Bactiguard Holding Ab's earnings presentation, Jul 14, 2026
Slide 1: Solid performance driven by revenue growth
Solid performance driven by revenue growth Q2 presentation Tuesday 14 July 2026 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Solid performance driven by revenue growth
Solid performance driven by revenue growth Key figures for Q2 2026 (Q2 2025) Highlights Q2 • 16% net sales growth (excl. currency) Total revenue 57.1 (52.1) MSEK • New agreement strengthens 35-year BD partnership Adj. EBITDA 5.6 (4.4) MSEK • Growing use in patients with Net loss -8.2 (-8.1) MSEK Zim
Slide 3: BD – solidifying the long-term partnership
BD – solidifying the long-term partnership • Signing of long-term agreement to continue and deepen collaboration since 1990 • BD revenues up 50% vs. weak Q2 2025, +8% year-to-date (excluding currency effects) • Bactiguard supported BD launches in Nordics, Poland and parts of the Middle-East At a gla
Slide 4: Zimmer Biomet – Bactiguard growing use in trauma patients
Zimmer Biomet – Bactiguard growing use in trauma patients • Fixed fees bring continued stability • Continued execution on main activities to support future growth – MDR transition and ZNN Bactiguard clinical studies, with first study portion now complete • Significant headroom for growth as coated i
Slide 5: Advancing business development activities across our strategic therapeutic areas
Advancing business development activities across our strategic therapeutic areas Partnership snapshot Q2 2026 Material transfer Application development Exclusivity partnership License partnership agreement partnership Orthopedics Cardiology Neurology Urology Vascular access Other 5 Average 5-7 years
Slide 6: Wound Management – one of the strongest quarters ever
Wound Management – one of the strongest quarters ever • 67% revenue growth in Q2, 25% for the first half of 2026 (excluding currency effects) • Hydrocyn aqua led the way, with growth across the Middle East, Europe and Asia • Continued investment in product availability and the Penang, Malaysia opera
Slide 7: Total revenue increased 12% excl. currency in Q2 driven by high growth from BD and Wound Management
Total revenue increased 12% excl. currency in Q2 driven by high growth from BD and Wound Management Revenue development constant currency MSEK Other revenues BIP portfolio Wound Management portfolio Total license revenue Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 228,7 230,9 0,9 1
Slide 8: Despite high growth from the BD partnership, License revenues were down in Q2 due to high comparisons for ZB
Despite high growth from the BD partnership, License revenues were down in Q2 due to high comparisons for ZB License revenue development constant currency MSEK Application development partners Exclusivity partners License partners Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 152,3 1
Slide 9: Total operating costs (OPEX) increased 11% in Q2, but almost flat on YTD basis
Total operating costs (OPEX) increased 11% in Q2, but almost flat on YTD basis Total operating costs (OPEX) development MSEK Personnel costs Other external expenses Other operating expenses Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 153,7 155,0 1,5% 95,4 97,2 83,3 84,5 11,3% 46,6
Slide 10: We increased our Adjusted EBITDA to SEK 5.6 million in Q2 and RTM increased to SEK 40.5 million
We increased our Adjusted EBITDA to SEK 5.6 million in Q2 and RTM increased to SEK 40.5 million Adjusted EBITDA development MSEK Adjusted EBITDA Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 43.8 40.5 -3.2 13.8 +1.2 10.6 4.4 5.6 2025 2026 2025 2026 2025 2025/26 10 Source: Bactiguard
Slide 11: We delivered solid cash flow from operations of SEK 12.4 million and SEK 43.5 in cash position at end of Q2
We delivered solid cash flow from operations of SEK 12.4 million and with SEK 43.5 in cash position at end of Q2 Cash flow for the period and total cash development MSEK 12,4 -0,7 -4,3 0,7 43,5 35,3 Cash end Cash flow Cash flow Cash flow Exchange Cash end of Q1 2026 from operating from investing fro
Slide 12: Continue to execute on strategy towards 2030 targets
Continue to execute on strategy towards 2030 targets Strategic focus Targets by year-end 2030 application areas Advance current and License partnerships develop new partnerships >10 in either exclusivity or license partnership R&D Medical Continue to invest in key >200 MSEK EBITDA knowledge areas Re
Slide 13: Key Takeaways
Key Takeaways 16% net sales growth BD agreement restated Zimmer Biomet momentum Broad-based growth with New agreement deepens 35-year Growing coated-implant use in improving EBITDA and cash flow global partnership patients and double-digit product sales growth Wound Management +67% Strong partner pi
Slide 14: Questions & Answers
Questions & Answers Q2 presentation Christine Lind Patrick Bach CEO CFO
Slide 15: Additional financial information
Additional financial information
Slide 16: Appendix – Reported revenue
Appendix – Reported revenue Reported Revenue development MSEK Other revenues BIP portfolio Wound Management portfolio Total license revenue Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 228,7 217,9 0,9 12,8 0,0 12,8 62,7 69,0 -9,6% 114,9 103,9 7,6 0,9 9,6% 0,0 7,5 33,0 57,1 39,3 152,
Slide 17: Appendix – Reported License revenue
Appendix – Reported License revenue Reported License revenue development MSEK Application development partners Exclusivity partners License partners Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 152,3 0,0 0,3 136,1 0,0 1,4 -22,1% 73,4 0,0 0,0 152,0 57,2 134,7 -5,9% 0,0 1,2 34,1 32,1
Slide 18: Appendix - EBITDA
Appendix - EBITDA EBITDA development MSEK EBITDA Second quarter (Apr-Jun) Year to date (Jan-Jun) Full year RTM 43.8 36.7 -7.0 13.8 -1.8 6.8 4.4 2.6 2025 2026 2025 2026 2025 2025/26 18 Source: Bactiguard Holding AB, Interim report Q1 2025, p. 14